Advertisement

International Journal of Hematology

, Volume 80, Issue 5, pp 435–440 | Cite as

Treatment of Hematologic Malignancies with Alternate Hemibody Irradiation Combined with High-Dose Chemotherapy: A Single-Center Experience

  • Jialin Wei
  • Mei Wang
  • Dehui Zou
  • Donglin Yang
  • Rui Li
  • Jun Ning
  • Sizhou Feng
  • Mingzhe Han
Article

Abstract

The objective of this study was to evaluate the clinical outcome of the treatment of hematologic malignancies with alternate hemibody irradiation (AHBI) combined with high-dose chemotherapy. Seventeen patients with hematologic malignancies were treated with AHBI combined with high-dose chemotherapy. Following high-dose chemotherapy, upper hemibody irradiation (UHBI) and lower hemibody irradiation (LHBI) were given sequentially in a dose of 6 to 9 Gy. UHBI was given 14 days (range, 12-22 days) after high-dose chemotherapy, and LHBI was performed 23 days (range, 7-34 days) after UHBI. Meanwhile, we treated a control group of 14 patients with acute lymphoblastic leukemia (ALL) with autologous hematopoietic stem cell transplantation (AHSCT). Hematopoietic reconstitution was observed in all of the patients. The median follow-up period was 927 days (range, 428-1446 days). The 3-year probabilities of disease-free survival (DFS) were 52.38% ± 13.47% for the patients in complete remission who underwent AHBI. No patient died of AHBI-related toxicity. The 3-year DFS rates for the 2 groups of patients with ALL were not significantly different (47.73% ± 17.55% in the AHBI group and 53.88% ± 14.08% in the AHSCT group; P >.05). AHBI combined with high-dose chemotherapy is a feasible approach for patients with hematologic malignancies and has the advantages of a desirable effectiveness, low costs, simple operation, and acceptable side effects.

Key words

Hematologic malignancy Alternate hemibody irradiation Stem cell transplant 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-iden- tical relatives in patients with hematologic cancers. N Engl J Med. 2001;344:175–181.CrossRefPubMedGoogle Scholar
  2. 2.
    Martens ACM, van Bekkum DW, Hagenbeek A. Minimal residual disease in leukemia: studies in an animal model for acute myelo- cytic leukemia (BNML). Int J Cell Cloning. 1990;8:27–38.CrossRefPubMedGoogle Scholar
  3. 3.
    Martens ACM, Hagenbeek A. Kinetics of normal hemopoietic stem cells during leukemia growth before and after induction of a complete remission: studies in a rat model for human acute myelo- cytic leukemia (BNML). Leuk Res. 1987;11:453–459.CrossRefPubMedGoogle Scholar
  4. 4.
    Chu J. Experimental studies on the elimination of minimal residual leukemia in vivo by alternate half body irradiation [in Chinese]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1993;15:12–16.PubMedGoogle Scholar
  5. 5.
    Chu J, Zhao J, Ying H, et al. Eradication of the residual leukemic cells by the regimen of alternate half body irradiation [in Chinese]. Chin J Hematol. 1994;15:236–239.Google Scholar
  6. 6.
    Bensinger W, Singer W, Appelbaum F, et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood. 1993;81:3158–3163.PubMedGoogle Scholar
  7. 7.
    Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute non- lymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75:27–32.PubMedGoogle Scholar
  8. 8.
    Quasim MM. Half body irradiation (HBI) in metastatic carcinomas. Clin Radiol. 1981;32:215–219.CrossRefGoogle Scholar
  9. 9.
    Singer CRJ, Tobias JS, Giles F, Rudd GN, Blackman GM, Richards JD. Hemibody irradiation: an effective second-line therapy in drug- resistance multiple myeloma. Cancer. 1989;63:2446–2451.CrossRefPubMedGoogle Scholar
  10. 10.
    Mao Y, You Y, Chu J, et al. Treatment of acute lymphocytic leukemia by alternate half body irradiation: the first case report [in Chinese]. Chin J Hematol. 1996;17:585.Google Scholar
  11. 11.
    Wu Q, Ma H, Yu S, et al. Clinical observation of treatment of the residual disease in acute leukemia patients by alternate half body irradiation. Cancer. 2001;20:515–518.Google Scholar
  12. 12.
    Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol. 2003;10:284–289.CrossRefPubMedGoogle Scholar
  13. 13.
    Han M, Feng S, Li C, et al. Outcome of autologous bone marrow transplantation in 73 patients with acute leukemia [in Chinese]. Chin J Hematol. 1998;19:422–424.Google Scholar
  14. 14.
    Kolb HJ, Bender-Gotze C. Late complications after allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1990;6:61–72.PubMedGoogle Scholar
  15. 15.
    Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood. 1995;85:1151–1168.PubMedGoogle Scholar
  16. 16.
    Powles R, Mehta J, Singhal S, et al. Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult lymphoblastic leukemia in first remission: 50 cases from a single center. Bone Marrow Transplant. 1995;16:241–247.PubMedGoogle Scholar
  17. 17.
    Doubek M, Mayer J, Koristek Z. Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy: experience of a single center [in Czech]. Cas Lek Cesk. 2002;141:122–126.PubMedGoogle Scholar
  18. 18.
    Meloni G, Trisolini SM, Capria S. How long can we give interleukin-2? Clinical and immunological evaluation of AML patients after 10 or more years of IL2 administration. Leukemia. 2002;16:2016–2018.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2004

Authors and Affiliations

  • Jialin Wei
    • 1
  • Mei Wang
    • 1
  • Dehui Zou
    • 1
  • Donglin Yang
    • 1
  • Rui Li
    • 1
  • Jun Ning
    • 1
  • Sizhou Feng
    • 1
  • Mingzhe Han
    • 1
  1. 1.Institute of HaematologyBlood Disease Hospital, CAMS and PUMCTianjinPeople’s Republic of China

Personalised recommendations